Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.
Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.
Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.
Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process.